Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Nov;18(2):87–90. doi: 10.1007/BF00205740

Role of first stimulating agents in the production of tumor necrosis factor

Katsuyuki Haranaka 1, Nobuko Satomi 1, Akiko Sakurai 1, Ruriko Haranaka 2
PMCID: PMC11039092  PMID: 6391657

Abstract

The conditions and kinetics of tumor necrosis factor (TNF) production were examined. For TNF production, dual stimulation is necessary. Priming agents such as BCG, Corynebacterium parvum, and zymosan, which can stimulate the reticuloendothelial system (RES), are good substances for TNF production with the aid of lipopolysaccharide. Wide differences are observed in TNF producibility among different priming agents. The producibility of TNF depends on the degree of stimulation of the RES by the priming agents. Those priming agents, e.g., Propionibacterium acnes and Corynebacterium anaerobium, that are able to induce substantial RES hyperplasia are also able to induce high levels of TNF activity. Following administration of large doses of BCG or zymosan, mice were found to produce TNF activity. However, PPD, OK 432, PSK, and Choreito were unable to induce TNF activity.

Keywords: Cancer Research, Tumor Necrosis, Tumor Necrosis Factor, Acne, Large Dose

References

  • 1.Algire GH, Legallais FY, Anderson BF. Vascular reactions of normal and malignant tissues in vivo. V. Role of hypotension in action of bacterial polysaccharide on tumors. J Natl Cancer Inst. 1952;12:1279. [PubMed] [Google Scholar]
  • 2.Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Green S, Dobrjansky A, Chiasson MA, Carswell E, Schwartz MK, Old LJ. Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in mouse. J Natl Cancer Inst. 1977;59:1519. doi: 10.1093/jnci/59.5.1519. [DOI] [PubMed] [Google Scholar]
  • 4.Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med. 1981;51:191. [PubMed] [Google Scholar]
  • 5.Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984;34:263. doi: 10.1002/ijc.2910340219. [DOI] [PubMed] [Google Scholar]
  • 6.Haranaka K, Satomi N, Sakurai A (1984b) Differences in tumor necrosis factor producibility among rodents. Br J Cancer 50 No 3
  • 7.Haranaka K, Satomi N, Sakurai A (1984c) Role of lipid A in the production of tumor necrosis factor and differences of antitumor activity between tumor necrosis factor and lipopolysaccharide. Tohoku J Exp Med (in press) [DOI] [PubMed]
  • 8.Helson L, Helson C, Green S. Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol. 1979;47:53. doi: 10.1159/000162922. [DOI] [PubMed] [Google Scholar]
  • 9.Männel DN, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor) Infect Immun. 1980;30:523. doi: 10.1128/iai.30.2.523-530.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Murayama T, Natsuume-Sakai S, Ryoyama K, Koshimura S. Studies of the properties of a streptococcal preparation, OK 432 (NSC-B116209), as an immunopotentiator. II. Mechanism of macrophage activation by OK-432. Cancer Immunol Immunother. 1982;12:141. [Google Scholar]
  • 11.Oettgen HF, Carswell EA, Kassel RL, Fiore N, Williamson B, Hoffman MK, Haranaka K, Old LJ. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res. 1980;75:213. doi: 10.1007/978-3-642-81491-4_32. [DOI] [PubMed] [Google Scholar]
  • 12.Old LJ. Tumor necrosis factor. Clin Bull. 1976;6:118. [PubMed] [Google Scholar]
  • 13.Old LJ. Cancer immunology: The search for specificity. Cancer Res. 1981;41:361. [PubMed] [Google Scholar]
  • 14.Old LJ, Clarke DA, Benecerraf B. Effect of Bacillus Calmette-Guérin infection on transplanted tumors in the mouse. Nature. 1959;4682:291. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
  • 15.Ribi EE, Granger DL, Milner KC, Strain SM. Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst. 1975;55:1253. doi: 10.1093/jnci/55.5.1253. [DOI] [PubMed] [Google Scholar]
  • 16.Ruff MR, Gifford GE. Tumor necrosis factor. In: Pick E, editor. Lymphokines, vol 2. New York: Academic Press; 1981. p. 235. [Google Scholar]
  • 17.Saito M, Ebina T, Koi M, Yamaguchi T, Kawada Y, Ishida N. Induction of interferon-γ in mouse spleen cells by OK432, a preparation of Streptococcus pyrogenes . Cell Immunol. 1982;68:187. doi: 10.1016/0008-8749(82)90102-2. [DOI] [PubMed] [Google Scholar]
  • 18.Saito M, Aonuma E, Noda T, Nakadate I, Nanjo M, Ebina T, Ishida N. Antitumor effect of OK-432 — Effector cells induced in mouse spleen after intravenous injection of OK-432 were cytotoxic macrophages. Jpn J Cancer Chemother. 1983;10:1363. [Google Scholar]
  • 19.Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagi Y. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209) Cancer Chemother Rep. 1972;56:9. [PubMed] [Google Scholar]
  • 20.Satomi N, Haranaka K, Kunii O. Research on the production site of tumor necrosis factor. Jpn J Exp Med. 1981;51:317. [PubMed] [Google Scholar]
  • 21.Usui S, Urano M, Koike S, Kobayashi Y. Effect of PSK, a protein polysaccharide, on pulmonary metastases of a C3H mouse squamous cell carcinoma. J Natl Cancer Inst. 1976;56:185. doi: 10.1093/jnci/56.1.185. [DOI] [PubMed] [Google Scholar]
  • 22.Yoshikumi C, Nomoto K, Matsunaga K, Fujii T, Takeya K. Mouse strain difference in the expression of antitumor activity of PSK. Gann. 1975;66:649. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES